Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Exclusion Criteria

• •Pregnant or breastfeeding
• •Symptomatic or untreated brain metastases
• •Have previously received CLDN18.2 antibody drug conjugates (ADCs) or any ADC containing an auristatin payload (prior monoclonal antibody against CLDN18.2 may be eligible)
• •Have peripheral neuropathy Grade ≥2
• •Have history of non-infectious pneumonitis/interstitial lung disease
• •Have diagnosis of another malignancy, or history of systemic treatment for invasive cancer within last 3 years. Note: Patients with Stage I cancer who have received definitive local treatment and are considered unlikely to recur are eligible. Diagnosis of non-melanoma skin cancer, carcinoma in situ of the cervix or breast, or noninvasive tumor does not affect eligibility
• •Have active ocular surface disease at baseline (based on screening ophthalmic examination) as defined as symptomatic or Grade ≥2 disease involving the cornea
• •Have history of Grade ≥2 gastritis
• •Have serious concurrent illness or clinically relevant active bacterial, fungal or viral infection
• •Have a history of several allergic and/or anaphylactic reactions to known chimeric, human, or humanized antibodies, fusion proteins or known allergies to components of EO-3021, ramucirumab, or dostarlimab
• •Clinically significant cardiac disease, including but not limited to symptomatic congestive heart failure, unstable angina, acute myocardial infarction within 6 months of planned first dose, or unstable cardiac arrhythmia requiring therapy (including torsades de pointes)
• •Have history of allogenic hematopoietic stem cell transplantation or solid organ transplantation with ongoing systemic immunosuppressive therapy
• •Received any live vaccine within 30 days of enrollment
• •Patients who are not appropriate candidates for participation in this clinical study for any other reason as deemed by the Investigator
• •Expansion only: Have HER2+ disease as defined by American Society of Clinical Oncology-College of American Pathologists guidelines for gastric/GEJ adenocarcinoma
• •Ramucirumab Arms Only: Received prior treatment with ramucirumab and other VEGFR2 inhibitors
• •Dostarlimab Arms Only: Prior treatment with immune checkpoint inhibitors (ICI) including dostarlimab and other anti-PD-1, anti-PD-L1, etc.